The objective: The assessment of the severity, prevalence and five-year dynamics of anxiety and depression in those studied with rheumatic heart disease. Materials and methods. The study included 168 patients with rheumatic heart disease: mean age 58.69±0.47 years; 141 women (83.93 %) and 27 men (16.07 %). To assess anxiety and depression, the following scales were used: HADS
The high prevalence of anxiety and depressive disorders and their relationship with cardiovascular diseases has long been known. Anxiety and depression significantly affect patients' quality of life, their adherence to treatment and performance [1] . It is noted that people with depression often develop coronary artery disease, myocardial infarction, stroke and sudden death, even in the case of unexpressed depressive symptoms [2] . In addition, both the cardiovascular diseases themselves lead to anxiety and depressive disorders, and anxiety with depression affect heart rhythm disturbances, the duration of angina attacks and the frequency of coronary events. At the same time, anxiety disorders are associated with an increase in the risk of coronary artery disease (CAD) by 26-41 %, and cardiovascular disease by 52 % in the case of longterm follow-up [3, 4] . Literature indicates that the increase in the severity of depression by 1 point on the Zung self-assessment scale increases mortality by 8 % [5] . But data on the relationship between anxiety disorders and increased risk of mortality from coronary artery disease has not been obtained [3] . However, anxiety disorders may be associated with an increased risk of coronary events [6] . The outcome of most cardiovascular diseases is chronic heart failure (CHF), which largely determines their course and prognosis. The prevalence of anxiety and depressive disorders in patients with CHF of ischemic etiology ranges from 14 % to 60 % according to the literature. Severe depression is seen in 17.25 % of the subjects, moderate -in 20.9 % and mild -in 27.3 % [7] . According to the literature, the severity and frequency of anxiety and depressive disorders in CHF can be influenced by the following factors [8] [9] [10] [11] [12] : functional class (FC) of CHF (especially III and IV FC); its duration; the age of the patient (older or younger than 60 years); sex (in case of ejection fraction less than 40 % females dominate); concomitant pathology (diabetes mellitus); economic status (socially vulnerable patients and unemployed); level of education (lower level of education); place of residence (living in the city); degree of awareness on CHF (lack of information about CHF and methods of its treatment). Depression is an additional factor affecting the physical, mental and social activity of patients with CHF. Often accompanying CHF paroxysmal and permanent atrial fibrillation leads to increased anxiety and depression [1] . Depressive disorders also affect the life expectancy of patients with CHF. It is believed that the mortality of patients with depression is 25 % compared to 11.3 % of patients without signs of disorders. Data on the dynamic monitoring of patients with CHF due to acquired heart defects [13] and the incidence of anxiety and depression in such patients are few [14] .
The objective of the work was to assess the severity, prevalence and five-year history of anxiety and depression in subjects with chronic rheumatic heart disease (CRHD).
Materials and methods
The study included 168 patients with CRHD who underwent inpatient treatment at the regional cardiology dispensary and signed an informed consent. The average age of the subjects was 58.69±0.47 years; 141 women (83.93 %) and 27 men (16.07 %). From subjects diagnosed with CRHD we selected only patients who had mitral stenosis as a reliable symptom of rheumatic defect. The absence of mitral stenosis was the exclusion criterion.
To obtain more objective estimates of FC we used a 6-minute walk test. Twenty-two subjects (13.1 %) had FC I, 77 (45.8 %) -FC II, 60 (35.7 %) -FC III, 9 (5.4 %) -FC IV. In addition, dyspnea was assessed on a visual analog scale (VAS) of 100 mm. Echocardiography was carried out on Philips Affinity 50 with the assessment of the linear dimensions of the heart, the pressure gradients on the valves. The following scales of anxiety and depression assessment were used in the assessment of anxiety and depression: hospital anxiety and depression scale (HADS) with assessment: 0-7 -normal; 8-10 points -subclinically expressed anxiety/depression; 11 points and more -clinically expressed anxiety/depression. Depression Scale of the Center for Epidemiological Studies (CES-D) with assessment: 0-17 points -normal; 18-26 points -mild depression; 27-30 pointsmoderate depression; 31 points and above -severe depression. State-Trait Anxiety Inventory (STAI) with assessment of anxiety: up to 30 points -low, 31-44 points -moderate; 45 and more -high [15] with the assessment of state (SA) and trait anxiety (TA). TA reflects a person's predisposition to anxiety and suggests a tendency to perceive many situations as threatening. TA is activated by the perception of certain stimuli, which are regarded as dangerous for self-assessment and self-esteem. SA (or situational anxiety) is characterized by subjectively experienced emotions: tension, anxiety, nervousness and restlessness. SA occurs as an emotional reaction to a stressful situation and can be different in intensity and responsiveness over time.
Quality of life was assessed using the general questionnaire titled Short Form Medical Outcomes Study (SF-36 V. 1) evaluating the quality of life for the last 4 weeks with scores on 8 scales and forming two summary measures: physical and mental health component. Kansas City Cardiomyopathy Questionnaire (KCCQ) with an assessment of two total indicators: functional status and total clinical indicator. Specific for CHF Minnesota Living With Heart Failure Questionnaire (MHFLQ), consisting of 21 points. The scale of life quality assessment from the EuroQol Group EQ-5D questionnaire was also used. The IBM SPSS Statistics 23.0 software with t-test evaluation for independent samples, Kruskal-Wallis test and Pearson correlation was used for statistical processing of the obtained data. The differences were considered as statistically significant at p <0.05.
Results
Initially, the prevalence of CES-D depression in subjects with CRHD was: 39.9 % -normal; 38.7 %mild depression; 8.9 % -moderate depression; and 12.5 % severe depression. By HADS (depression): 39.9 % -normal; 36.3 % -subclinically expressed depression; 23.8 % -clinically significant depression. Incidence of anxiety by HADS (depression) was: 36.9 % -normal; 32.2 % -subclinically expressed anxiety; 30.9 % -clinically significant anxiety. According to STAI, mild SA occurred in 3.0 % of the subjects; moderate SA -in 33.3 % of the subjects; severe SA -63.7 % of the subjects. The prevalence of TA in STAI was low in 10.7 %; moderate in 52.4 %; high in 36.9 % of patients with CRHD. The average distance in 6-minute walk test in patients was 330.91±8.42 meters and for 5 years it slightly decreased to 324.92±8.42 meters, but the value remained within the range of CHF of FC II. Dyspnea, which is one of the main symptoms of CHF, although it increased according to VAS for dyspnea assessment from 47.21±2.90 mm to 50.58±3.74 mm, the increase was insignificant. When assessing the echocardiographic parameters (Tab. 1) there was a statistically significant increase in the size of the left atrium by 0.25 cm, the aortaby 0.12 cm and a decrease in mitral valve orifice area -by 0.10 cm 2 for five years. Pressure on the aortic valve also increased in patients with combined There were no significant differences in depressive and anxiety disorders between the groups. Depression and CES-D scores were consistent with mild depression, and the HADS score was subclinically expressed depression in both groups. On the HADS scale, there was also subclinically expressed anxiety in both groups. According to the STAI questionnaire, moderate anxiety for TA and high anxiety for SA was revealed both in the case of sinus rhythm and in the case of permanent AF. 
Discussion
Initially, patients with CRHD had a slight expression of depression and anxiety. The exception was the indicator of SA according to STAI, which had more than 45 points (48.00±0.95) and was consistent with the high level of anxiety. Although in the literature [15] for CHF of non-ischemic etiology, the level of SA is indicated at the level of 34.3±12.5, and TA -34.5±11.7, and the prevalence of anxiety according to HADS ranges from 24.7 % (moderate) to 32.6 % (high) [8] . During the five-year follow-up period of the study with CRHD there were no negative changes in terms of the 6-minute walk test and VAS for dyspnea. The mitral valve orifice area of 0.1 cm 2 decreased significantly, the linear dimensions of the left atrium increased by 0.25 cm and the quality of life in the physical health component of SF-36 deteriorated by 1.78, the functional status of KCCQ -by 1.55 and MHFLQ -by -3.99. Against this background, for 5 years there were no expressed negative and positive changes according to the questionnaires for anxiety and depression assessment. The only exception was the increase in anxiety according to HADS by 0.66 points. Changes in the indicators of anxiety and depression were obtained in the initial assessment of patients depending on FC of CHF. The severity of depressive disorders increased in subjects with III and IV FC of CHF. According to CES-D from 17.58±1.27 with FC I to 23.4±0.75 with FC IV, and according to HADS from 7.00±0.64 with FC I to 13.6±0.78 with FC IV, which is consistent with the literature data [8] . On the contrary, anxiety disorders decreased with FC III and IV: from 8.5±0.49 with FC I to 8.2±1.02 with FC IV according to HADS scale. According to STAI questionnaire there was also a reduction of anxiety indicators: according to SA from 47.58±1.22 (FC I) to 42.8±1.76 (FC IV), TA from 42.67±1.08 (FC I) to 40.4±1.85 (FC IV). After 5 years, the reverse pattern was observed: there was a decrease in depression on the CES-D and HADS in subjects with CHF NYHA III and IV and an increase of anxiety indicators on the HADS and STAI in comparison with patients with FC I and II; however, there was no statistical significance of the differences. However, the literature indicates that the level of depression should increase with longer duration of CHF [8] .
As it turned out, the presence of permanent AF in subjects with CRHD does not make an additional contribution to the worsening of anxiety and depressive disorders. Anxiety and depression indicators were mostly moderate in the group with AF and sinus rhythm, and did not differ significantly. The literature, on the contrary, indicates an increase in the level of anxiety by 18.2 % and depression by 20.9 % in comparison with patients without arrhythmia [1] . However, this pertains to patients with CHF of ischemic origin.
Since, on the one hand, the presence of anxiety and depression worsens the quality of life of people [11] , and on the other hand, the presence of anxiety and depression in itself is a manifestation and outcome of a reduced quality of life, the correlation of these indicators was assessed. Almost all the total scales of non-specific quality of life questionnaires showed an inverse significant correlation at the level of 0.01 in terms of depression and direct anxiety on the scales for SA and TA assessment of the STAI questionnaire with weak-to-moderate strength of relation. This means that the better the quality of life of patients with CRHD, the more pronounced the anxiety and the less pronounced the depression. Similar results were obtained for the CHF-specific MHFLQ questionnaire: the higher the MHFLQ indicator (worse quality of life), the more pronounced the depression and the less pronounced the anxiety. This is probably due to the fact that anxiety is an emotional reaction and with a prolonged low quality of life grows into depression, and the latter, according to literature, is closely related to the low quality of life [9] . Conversely, patients with better quality of life are more concerned about their health and have an increased level of anxiety.
Conclusion
Thus, in patients with CRHD the severity of anxiety and depression is insignificant and does not increase within five years of follow-up. Indicators of depression are more pronounced in the group of subjects with FC III and IV of CHF, as well as indicators of anxiety in patients with FC I and II of CHF. The increase in the indicators of depression in subjects with CRHD is associated with a deterioration in the quality of life. With the improvement of the quality of life, depressive manifestations decrease, and anxiety indicators increase.
